The MarketWatch News Department was not involved in the creation of this content. The dynamics of the acne vulgaris market are anticipated to change in the coming years owing to the increase in the ...
BRIDGEWATER, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing ...
The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020. The first-in-class ...
Please provide your email address to receive an email when new articles are posted on . Acne vulgaris may be driven by underlying systemic, immune-inflammatory pathways. Addressing those underlying ...
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the ...
NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will host a conference call today to discuss results from two Phase 3 clinical trials for Twyneo®, an ...
In a recent study published in the journal Nutrients, researchers review existing publications to determine the role of nutrition in the development of acne vulgaris. To this end, the complex ...
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that ...
The dynamics of the acne vulgaris market are anticipated to change in the coming years owing to the increase in the prevalent cases of acne vulgaris, along with the expected launch of emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback